Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation

Lymphoma

Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin

healthbook Times Oncology Hematology

Schmidt A

doi: 10.36000/hbT.OH.2020.06.025

Genitourinary CancerLymphoma

Incidental finding of non-Hodgkin's lymphoma in a patient affected by castration-sensitive prostate cancer: A case report

Medicine (Baltimore).

Pirozzi A, Cartenì G, Scagliarini S, Fusco M, Riccardi F

doi: 10.1097/MD.

Lymphoma

Nivolumab maintenance after salvage autologous stem cell transplantation results in long term remission in multiple relapsed primary cns lymphoma

Eur J Haematol.

Terziev D, Hutter B, Klink B, Stenzinger A, Stögbauer F, Glimm H, Fröhling S, Wickenhauser C, Jordan K, Hurtz HJ, Müller LP, Rüssel J, Weber T

doi: 10.1111/ejh.13072.

Lymphoma

Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin's lymphoma

J Clin Pharm Ther.

Tran PN, Pinter-Brown LC

doi: 10.1111/jcpt.12572.

Gynecologic Cancer

Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report

Gynecol Oncol Res Pract.

Paraghamian SE, Longoria TC, Eskander RN

doi: 10.1186/s40661-017-0038-9.

LeukemiaLymphoma

Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length

Leuk Lymphoma.

Ammann EM, Shanafelt TD, Wright KB, McDowell BD, Link BK, Chrischilles EA

doi: 10.1080/

Lymphoma

Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment

Leuk Lymphoma.

Papin A, Le Gouill S, Chiron D

doi: 10.1080/

Lymphoma

CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement

healthbook TIMS Oncology Hematology

Ring A, Müller A

doi: 10.36000/hbT.OH.2019.01.005

Radio-OncologyLymphoma

Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report

Neurol Med Chir (Tokyo).

Furuse M, Nonoguchi N, Omura N, Shirahata M, Iwasaki K, Inui T, Kuroiwa T, Kuwabara H, Miyatake SI

doi: 10.2176/nmc.cr.2016-0330.

Related content

Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin

Incidental finding of non-Hodgkin's lymphoma in a patient affected by castration-sensitive prostate cancer: A case report

Nivolumab maintenance after salvage autologous stem cell transplantation results in long term remission in multiple relapsed primary cns lymphoma

Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin's lymphoma

Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report

Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length

Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment

CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement

Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report